Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis

被引：0

作者：

Sridhar Murahari

Aimee L. Jalkanen

Samuel K. Kulp

Ching-Shih Chen

Jaime F. Modiano

Cheryl A. London

William C. Kisseberth

机构：

[1] The Ohio State University,Department of Veterinary Clinical Sciences, College of Veterinary Medicine

[2] The Ohio State University,Department of Veterinary Biosciences, College of Veterinary Medicine

[3] The Ohio State University,Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy

[4] University of Minnesota,Department of Veterinary Clinical Sciences, College of Veterinary Medicine

[5] University of Minnesota,Masonic Cancer Center

[6] Colorado State University,Current address: Department of Microbiology, Immunology and Pathology

来源：

BMC Cancer | / 17卷

关键词：

Apoptosis; AR-42; Dog; Histone deacetylase inhibitor; Osteosarcoma;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[1] Sensitivity of osteosarcoma cells to HDAC inhibitor AR-42 mediated apoptosis
Murahari, Sridhar
Jalkanen, Aimee L.
Kulp, Samuel K.
Chen, Ching-Shih
Modiano, Jaime F.
London, Cheryl A.
Kisseberth, William C.
BMC CANCER, 2017, 17
[2] ACTIVITY OF THE HISTONE DEACETYLASE (HDAC) INHIBITOR AR-42 IN A MURINE MALARIA MODEL
Chua, Ming Jang
Do, Darren
Bachu, Prabhakar
Reid, Robert
Fairlie, David
Skinner-Adams, Tina
Andrews, Kathy
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2017, 97 (05): : 493 - 493
[3] AR-42 induces apoptosis in human hepatocellular carcinoma cells via HDAC5 inhibition
Zhang, Mingming
Pan, Yida
Dorfman, R. G.
Chen, Zhaogui
Liu, Fuchen
Zhou, Qian
Huang, Shan
Zhang, Jun
Yang, Dongqin
Liu, Jie
ONCOTARGET, 2016, 7 (16) : 22285 - 22294
[4] HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide
Cordero-Nieves, Hector
Sborov, Douglas W.
Canella, Alessandro
Liu, Zhongfa
Consiglio, Jessica
Ni, Wenjun
Smith, Emily
Rizzotto, Lara
Efebera, Yvonne A.
Benson, Don M.
Cascione, Luciano
Mo Xiaokui
Byrd, John C.
Grever, Michael R.
Hofmeister, Craig C.
Pichiorri, Flavia
BLOOD, 2014, 124 (21)
[5] HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide
Canella, Alessandro
Nieves, Hector Cordero
Sborov, Douglas W.
Cascione, Luciano
Radomska, Hanna S.
Smith, Emily
Stiff, Andrew
Consiglio, Jessica
Caserta, Enrico
Rizzotto, Lara
Zanesi, Nicola
Stefano, Volinia
Kaur, Balveen
Mo, Xiaokui
Byrd, John C.
Efebera, Yvonne A.
Hofmeister, Craig C.
Pichiorri, Flavia
ONCOTARGET, 2015, 6 (31) : 31134 - 31150
[6] AR-42: A Pan-HDAC Inhibitor with Antitumor and Antiangiogenic Activities in Esophageal Squamous Cell Carcinoma
Zhu, Yuxuan
Yuan, Ting
Zhang, Yuan
Shi, Jianyou
Bai, Lan
Duan, Xingmei
Tong, Rongsheng
Zhong, Lei
DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 4321 - 4330
[7] Preclinical investigation of the novel histone deacetylase (HDAC) inhibitor AR-42 in the treatment of cancer-induced cachexia
Tseng, Yu-Chou
Kulp, Samuel
Lai, I-Lu
He, Wei
Bundschuh, Ralf
Frankhouser, David
Yan, Pearlly
Guttridge, Denis
Marcucci, Guido
Chen, Ching-Shih
Bekaii-Saab, Tanios
CANCER RESEARCH, 2014, 74 (19)
[8] Histone deacetylase inhibitor, AR-42, exerts antitumor effects by inducing apoptosis and cell cycle arrest in Y79 cells
Duan, Sujuan
Gong, Xiaona
Liu, Xing
Cui, Wenwen
Chen, Kaddie
Mao, Longbing
Jun, Sun
Zhou, Ruihao
Sang, Yi
Huang, Guofu
JOURNAL OF CELLULAR PHYSIOLOGY, 2019, 234 (12) : 22411 - 22423
[9] AR-42 Induces Apoptosis and Cell Cycle Arrest in Pancreatic Cancer
Yan, Y.
Wang, W.
TRANSPLANTATION, 2017, 101 (05) : 201 - 201
[10] A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas
Sborov, Douglas W.
Canella, Alessandro
Hade, Erinn M.
Mo, Xiaokui
Khountham, Soun
Wang, Jiang
Ni, Wenjun
Poi, Ming
Coss, Christopher
Liu, Zhongfa
Phelps, Mitch A.
Mortazavi, Amir
Andritsos, Leslie
Baiocchi, Robert A.
Christian, Beth A.
Benson, Don M.
Flynn, Joseph
Porcu, Pierluigi
Byrd, John C.
Pichiorri, Flavia
Hofmeister, Craig C.
LEUKEMIA & LYMPHOMA, 2017, 58 (10) : 2310 - 2318

← 1 2 3 4 5 →